Record NNP B-NP O
date NN I-NP O
: : O O
2163-02-25 CD O B-DATE
February NNP B-NP B-DATE
25 CD I-NP I-DATE
, , I-NP I-DATE
2163 CD O I-DATE
Barbara NNP B-NP B-DOCTOR
Chavez NNP I-NP I-DOCTOR
, , O O
M.D. NNP B-NP O
NMC . O B-HOSPITAL
Internal NNP B-NP O
Medicine NNP I-NP O
IMA NNP B-NP O
1 CD I-NP O
NXO NNP B-NP B-MEDICALRECORD
2-359 CD I-NP I-MEDICALRECORD
RE RB B-ADVP O
: : O O
William NNP B-NP B-PATIENT
Le FW O I-PATIENT
MRN NNP B-NP O
: : O O
054-00-99 CD O B-MEDICALRECORD
DOB VB B-VP O
: : O O
09/03/2089 CD O B-DATE
DOS VB B-VP O
: : O O
02/25/2163 CD O B-DATE
Dear NNP B-NP O
Dr NNP I-NP O
Chavez NNP I-NP B-DOCTOR
, , O O
Mr. NNP B-NP O
William NNP I-NP B-PATIENT
Le NNP I-NP I-PATIENT
return NN I-NP O
for IN B-PP O
follow-up JJ B-NP O
in IN B-PP O
the DT B-NP O
Neurology NNP I-NP O
clinic NN I-NP O
today NN B-NP O
. . O O
He PRP B-NP O
still RB B-ADVP O
has VBZ B-VP O
significant JJ B-NP O
difficulty NN I-NP O
walking VBG I-NP O
, , O O
and CC O O
he PRP B-NP O
is VBZ B-VP O
falling VBG I-VP O
frequently RB B-ADVP O
at IN B-PP O
home NN B-NP O
. . O O
He PRP B-NP O
has VBZ B-VP O
not RB I-VP O
sustained VBN I-VP O
any DT B-NP O
significant JJ I-NP O
injuries NNS I-NP O
. . O O
He PRP B-NP O
has VBZ B-VP O
numbness NN B-NP O
and CC I-NP O
paresthesias NNS I-NP O
of IN B-PP O
his PRP$ B-NP O
feet NNS I-NP O
, , O O
but CC O O
there EX B-NP O
has VBZ B-VP O
been VBN I-VP O
no DT B-NP O
interval NN I-NP O
change NN I-NP O
in IN B-PP O
his PRP$ B-NP O
symptoms NNS I-NP O
since IN B-PP O
his PRP$ B-NP O
last JJ I-NP O
visit NN I-NP O
in IN B-PP O
November NNP B-NP B-DATE
2162 CD I-NP I-DATE
. . O O
Medications NNS B-NP O
: : O O
Neurontin NNP B-NP O
300mg NNP I-NP O
TID NNP I-NP O
, , O O
Lasix NNP B-NP O
40mg CD I-NP O
daily JJ I-NP O
, , I-NP O
aspirin NN I-NP O
, , O O
Atenolol NNP B-NP O
50mg CD I-NP O
daily JJ I-NP O
, , I-NP O
Zetia NNP I-NP O
10mg CD I-NP O
, , O O
Pravastatin NNP B-NP O
20mg CD I-NP O
, , O O
Nexium NNP B-NP O
and CC O O
multi JJ B-NP O
vitamins NNS I-NP O
. . O O
Examination NNP B-NP O
: : O O
reveals VBZ B-VP O
that IN B-PP O
strength NN B-NP O
testing NN I-NP O
in IN B-PP O
the DT B-NP O
legs NNS I-NP O
is VBZ B-VP O
normal JJ B-ADJP O
. . O O
He PRP B-NP O
has VBZ B-VP O
absent JJ B-NP O
deep JJ I-NP O
tendon VBP I-NP O
reflexes NNS I-NP O
of IN B-PP O
the DT B-NP O
ankles NNS I-NP O
, , O O
trace NN B-NP O
to TO B-VP O
1+ VB I-VP O
at IN B-PP O
the DT B-NP O
knees NNS I-NP O
. . O O
Romberg NNP B-NP O
's POS B-NP O
test NN I-NP O
is VBZ B-VP O
positive JJ B-ADJP O
, , O O
and CC O O
the DT B-NP O
patient NN I-NP O
has VBZ B-VP O
difficulty NN B-NP O
standing VBG I-NP O
without IN B-PP O
assistance NN B-NP O
. . O O
Despite IN B-PP O
the DT B-NP O
degree NN I-NP O
of IN B-PP O
sensory JJ B-NP O
ataxia NN I-NP O
, , O O
he PRP B-NP O
is VBZ B-VP O
still RB B-ADVP O
able JJ B-ADJP O
to TO B-VP O
feel VB I-VP O
position NN B-NP O
sense NN I-NP O
at IN B-PP O
the DT B-NP O
metatarsophalangeal NN I-NP O
joints NNS I-NP O
in IN B-PP O
his PRP$ B-NP O
feet NNS I-NP O
. . O O
Vibration NN B-NP O
and CC O O
pinprick JJ B-NP O
sensation NN I-NP O
are VBP B-VP O
diminished VBN I-VP O
. . O O
Data NNP B-NP O
Review NNP I-NP O
: : O O
The DT B-NP O
patient NN I-NP O
does VBZ B-VP O
have VB I-VP O
a DT B-NP O
persistent JJ I-NP O
low JJ I-NP O
concentration NN I-NP O
of IN B-PP O
monoclonal JJ B-NP O
protein NN I-NP O
in IN B-PP O
the DT B-NP O
slow JJ I-NP O
gamma NN I-NP O
region NN I-NP O
. . O O
This DT B-NP O
is VBZ B-VP O
unchanged JJ B-ADJP O
compared VBN B-VP O
to TO B-PP O
the DT B-NP O
previous JJ I-NP O
study NN I-NP O
done VBN B-VP O
in IN B-PP O
February NNP B-NP B-DATE
2162 CD I-NP I-DATE
. . O O
This DT B-NP O
most RBS I-NP O
likely JJ I-NP O
is VBZ I-NP O
a DT B-NP O
MGUS. NNP I-NP O
Impression NN B-NP O
and CC I-NP O
Recommendation NNP I-NP O
: : O O
The DT B-NP O
patient NN I-NP O
has VBZ B-VP O
poorly RB I-VP O
controlled VBN I-VP O
diabetes NNS B-NP O
, , O O
complicated VBN B-VP O
by IN B-PP O
polyneuropathy NN B-NP O
. . O O
The DT B-NP O
monoclonal JJ I-NP O
protein NN I-NP O
is VBZ B-VP O
an DT B-NP O
incidental JJ I-NP O
finding NN I-NP O
and CC O O
is VBZ B-VP O
probably RB B-ADVP O
not RB O O
accounting VBG B-VP O
for IN B-PP O
his PRP$ B-NP O
peripheral JJ I-NP O
neuropathy NN I-NP O
. . O O
Given VBN B-VP O
that IN B-PP O
the DT B-NP O
monoclonal JJ I-NP O
protein NN I-NP O
has VBZ B-VP O
not RB I-VP O
changed VBN I-VP O
in IN B-PP O
concentration NN B-NP O
or CC I-NP O
character NN I-NP O
I PRP B-NP O
do VBP B-VP O
not RB I-VP O
believe VB I-VP O
that IN B-SBAR O
there EX B-NP O
is VBZ B-VP O
a DT B-NP O
need NN I-NP O
for IN B-PP O
additional JJ B-NP O
testing NN I-NP O
at IN B-PP O
this DT B-NP O
stage NN I-NP O
. . O O
He PRP B-NP O
will MD B-VP O
continue VB I-VP O
with IN B-PP O
Neurontin NNP B-NP O
to TO B-VP O
manage VB I-VP O
his PRP$ B-NP O
neuropathic JJ I-NP O
symptoms NNS I-NP O
. . O O
I PRP B-NP O
have VBP B-VP O
urged VBN I-VP O
him PRP B-NP O
to TO B-VP O
try VB I-VP O
and CC I-VP O
maintain VB I-VP O
good JJ B-NP O
diabetic NN I-NP O
control NN I-NP O
. . O O
Follow-up NN B-NP O
in IN B-PP O
6 CD B-NP O
months NNS I-NP O
Sincerely RB B-ADVP O
, , O O
Charles NNP B-NP B-DOCTOR
Tisdale NNP I-NP I-DOCTOR
